Latest Health News

Jayride Group Limited’s shares have been suspended from trading on the ASX following concerns over its financial health and a critical auditor’s disclaimer. The suspension highlights significant regulatory scrutiny and investor risk.

Eildon Capital Group has updated investors on a default notice issued to the borrower at Kings-Newport Village, emphasizing that the default relates to a site outside its secured loan facility.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.

Turners Automotive Group Limited has announced a fully franked ordinary dividend for the quarter ending June 2025, accompanied by a dividend reinvestment plan offering a 2% discount.

Turners Automotive Group has declared a higher Q1 FY26 dividend of 7 cents per share, up from 6 cents last year, reflecting steady financial health and shareholder returns.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

Micro-X has landed a $3.3 million order from the Malaysian Ministry of Health for its Rover Plus mobile X-ray units, marking a significant step in its Southeast Asian expansion. Delivery is set to begin in October 2025.

Select Harvests updates on its 2025 almond crop, revealing a slightly smaller harvest than forecast but a strong reduction in net debt and a promising 2026 bloom outlook.

Bank of Queensland announces a $170 million goodwill impairment in its retail banking unit for FY25, reflecting structural industry changes but maintaining strong cash earnings and capital ratios.

European Lithium Limited will lift its trading suspension on 3 October 2025 following the release of its Annual Financial Report, marking a key milestone for investors.

CONNEQT Health has disclosed significant revisions to its 2025 financial results, highlighting increased losses driven by a larger-than-expected fair value write-down on its inHealth investment and a heightened inventory provision.